利多组套式引物的测庚型肝炎病毒RNA

利用庚型肝炎病毒ＮＳ３－５区序列合成了四组套式引物，建立了灵敏，特异的 型肝炎病毒ＲＮＡ双扩增聚合酶链反应检测方法，用此方法检测了１０份庚型肝炎病毒抗体阳性患者血清及１０份阴性的健康人血清。前者不同组引物的检出率为ＮＳ３（１）引物９份了是性，ＮＳ３（２）引物８份阳性，ＮＳ４引物４份阳性，ＮＳ５（１）引物５份阳性，ＮＳ５（２）引物９份阳性；后者各组引物匀为阴性。结果表明，庚型肝炎病毒不同区域引物用于     

聚合酶链反应鉴定丙型肝炎病毒母婴传播的状态及其意义

采用多种方法，动态检测了１１例丙型肝炎病毒（ＨＣＶ）感染的孕妇所生的婴儿血抗－ＨＣＶ和ＨＣＶＲＮＡ。发现用合成肽酶联免疫吸附试验（ｓｐＥＬＩＳＡ）检测婴儿抗－ＨＣＶ阳性率（２３．５２％）显著低于第二代重组抗原ＥＬＩＳＡ（２ｎｄＥＬＩＳＡ）（４１．１８％）（Ｐ＜０．０５）；用２ｎｄＥＬＩＳＡ检测，６例婴儿脐血和静脉血抗－ＨＣＶ阳性，５例持续１～５月阴转，１例阳性持续１３个月。经重组免疫印迹试验（ＲＩＢＡ）鉴定，４例阳性，２例可疑阳性。用逆转录聚合酶链反应（ＲＴ－ＰＣＲ）检测ＨＣＶＲＮＡ，５例阳性，３例于生后１～６个月自然阴转，２例持续阳性分别达９个月和１３个月。提示检测抗－ＨＣＶ判断ＨＣＶ母婴传播的状态受到婴儿抗－ＨＣＶ产生水平低下、母体抗－ＨＣＶ的被动输入和不同检测方法的影响，用ＲＴ－ＰＣＲ检测ＨＣＶＲＮＡ是判断母婴传播更可靠的指标。     

用逆转录-套式聚合酶链反应检测我国不同临床型肝炎/肝病患者中庚型肝炎病毒感染

目的为了研究庚型肝炎病毒（ＨＧＶ）在我国的感染状况。方法根据已发表的ＨＧＶ的５’端非编码区（５’－ＵＴＲ区）及螺旋酶区（ＮＳ３区）两段高度保守的基因序列分别设计两套引物，用逆转录－套式聚合酶链式反应（ＲＴ－ｎｅｓｔｅｄＰＣＲ）检测ＨＧＶＲＮＡ。结果从北京、秦皇岛、河南等地采集各种肝病患者及职业献血员血清３５４份，ＨＧＶＲＮＡ阳性７９份，阳性率为２２．３％。其中已确定的临床型肝炎／肝病患者２５４例，ＨＧＶＲＮＡ阳性者为５０例，阳性率为１９．６％。原因不明的或非甲～戊型肝炎患者４３例，ＨＧＶＲＮＡ阳性者为１３例，阳性率为３０．２％。丙型肝炎阳性的职业献血员５７例，ＨＧＶＲＮＡ阳性者为１６例，阳性率为３０．２％。结论提示ＨＧＶ感染在我国多种人群中普遍存在，它不仅可能是引起非甲～戊型肝炎的重要病原之一，也可能是引起输血后肝炎的病原因子     

多重引物聚合酶链反应扩增丙型肝炎病毒基因及基 …

利用聚合酶链反应（ＰＣＲ）技术对丙型肝炎病毒（ＨＣＶ）的５’－非编码区（５’－ＮＣＲ）、Ｃ及ＮＳ４基因区的３对引物分别及同时扩增，检测８０例抗－ＨＣＶ阳性患者的血清ＨＣＶ ＲＮＡ，并进行了ＨＣＶ基因分型研究。各不同引物所介导的ＰＣＲ检出ＨＣＶ ＲＮＡ的结果为：５’－ＮＣＲ基因区６０％（４８／８０），Ｃ基因区３７％（３０／８０），ＮＳ４基因区３０％（２４／８０）。以上３对引物同时扩增仅４２％（３４／     

乌鲁木齐市部分高危人群庚型肝炎病毒感染现状及5′ UTR区基因序列分析

新疆地处我国西部边陲 ,存在着各型肝炎散发流行的危险因素 ,庚型肝炎病毒在乌鲁木齐市的流行现状尚未见报道。在新疆医科大学第一附院收集了2 67份各类人群的血清 ,用酶标法检测血清中庚型肝炎病毒抗体 (抗 ＨＧＶ) ,再以庚型肝炎病毒ＮＳ3区为引物运用ＲＴ ＰＣＲ法对抗 ＨＧＶ(阳性 )血清进行庚型肝炎病毒核酸 (ＨＧＶＲＮＡ)的扩增检测 ,阳性扩增产物为 83ｂｐ。最后 ,选择该病毒 5′非编码区为引物对第一次ＲＴ ＰＣＲ扩增ＨＧＶＲＮＡ(阳性 )血清 ,再次进行163.ｃｏｍ)ＲＴ ＰＣＲ扩增 ,阳性扩增产物为 1 90ｂｐ ,对第二次扩增ＨＧＶ…     

输血后丙型肝炎病毒非结构区抗体和丙氨酸转氨酶的动态分析

利用重组的丙型肝炎病毒非结构区（ＨＣＶＮＳ５）抗原建立了酶免疫试验（ＥＩＡ），对２５例输血后丙型肝炎进行了不同区抗体及丙氨酸转氨酶（ＡＬＴ）的动态研究，同时对１５６例慢性丙型肝炎患者血清进行ＨＣＶＲＮＡ和抗－ＮＳ５平行检测，两者符合率为６４．１％。抗－ＮＳ５抗体首次检出时间为３０～５７５天（１８２．９±１６８．５），晚于ＡＬＴ异常和其他区抗体的出现时间。在感染后１，３，６，１２和２４个月后抗－ＮＳ５的阳性率分别为２８％，４０％，５２％，６８％和７６％。抗－ＮＳ５的动态变化类型为四种：一过性阳性、间歇性阳性、持续性阳性和２年内持续阴性     

血清学标志阴性的非甲～戊型肝炎的病原学研究

目的对血清学标志阴性的非甲～戊型肝炎进行病原学研究。方法用ＨＢＶＰＣＲ、ＨＣＶＲＴ－ＰＣＲ和ＨＥＶＲＴ－ＰＣＲ分别检测血清学标志阴性的非甲～戊型肝炎患者血清，并对其部分阳性产物进行克隆测序。结果８７例非甲～戊型肝炎血清ＨＢＶＤＮＡ均为阴性，９例（１０．３％）为ＨＣＶＲＮＡ阳性，部分经测序证实为ＨＣＶ１ｂ亚型；余７８例为ＨＢＶＤＮＡ和ＨＣＶＲＮＡ均阴性。该７８例中，１４例因无血清未作ＨＥＶＲＮＡ检测，余６４例中４９例（７６．６％）为ＨＥＶＲＮＡ阴性，１５例（２３．４％）为ＨＥＶＲＮＡ阳性。经序列分析显示，其中９例为典型的中国ＨＥＶ株基因序列，６例变异较大，与典型的中国株基因序列的同源性仅为８０％左右。４９例ＨＢＶＤＮＡ、ＨＣＶＲＮＡ和ＨＥＶＲＮＡ均阴性的血清中１６例（３２．６％）ＨＧＶＲＮＡ阳性。由此可见，该８７例中至少有９例为ＨＣＶ感染，１５例为ＨＥＶ感染，１６例为ＨＧＶ感染。结论对血清学标志阴性的非甲～戊型肝炎的病人应该用ＰＣＲ法进行病原学分型，以明确其诊断     

庚型肝炎病毒致病性的初步研究

目的 探讨庚型肝炎病毒（ＨＧＶ）的致病性。方法 应用ＲＴ－ｎＰＣＲ检测３６８例肝炎患者血清ＨＧＶ ＲＮＡ和血清酶的变化,并对其中１例单独庚型肝炎肝硬化病例进行肝脏活组织是检测。结果 在７１例急性黄疸型肝炎中检出单纯性ＨＧＶ ＲＮＡ阳性７例,１５５例慢性肝炎中检出单纯性ＨＧＶ ＲＮＡ阳性２２例,５１例肝硬化中检出单纯ＨＧＶ ＲＮＡ阳性３例。其中１例肝穿组织免疫组化证实为ＨＧＶ ＮＳ ５Ａｇ阳性。结论 争性黄疸型肝炎及乙、丙型肝炎病毒携带者,其慢性肝炎、肝硬化和肝癌中均可检出ＨＧＶ ＲＮＡ,ＨＧＶ感染可为单独感中与乙／丙型肝炎病毒混合或重叠感染,肝脏病理和免疫组化检查证实庚型肝炎病毒是一种嗜肝病毒,其定位主要存在于细胞浆内,可引起慢性病毒性肝炎甚至肝硬化。庚型肝炎病毒很可能具有致病性。     

逆转录－巢式聚合酶链反应检测庚型肝炎病毒RNA方法的建立及初步应用

庚型肝炎病毒（ＨＧＶ）基因组为单链、正股ＲＮＡ，全长９３９２ｂｐ。根据５’－非编码区基因序列设计合成两对引物。随机选取酶联抗－ＨＧＶ阳性病人血清３份，阴性病人血清６份，应用逆转录－巢式聚合酶链反应进行检测。结果２份抗－ＨＧＶ阳性血清可见较强的特异扩增带，１份抗－ＨＧＶ阳性血清可见较弱的特异扩增带，其余６份抗－ＨＧＶ阴性血清均无特异性扩增带。特异扩增片断大小与设计相符，并经序列分析及Ｓｏｕｔｈｅｒｎ杂交给予证实。     

186例病毒性肝炎患者血清中庚型肝炎病毒RNA的检测

１８６例病毒性肝炎患者血清中庚型肝炎病毒ＲＮＡ的检测王瑞烈谢建媚秦小超曹赋应用逆转录－聚合酶链反应法（ＲＴ－ＰＣＲ）检测了１８６例住院的病毒性肝炎患者血清中庚型肝炎病毒ＲＮＡ。１材料和方法１．１检测对象为１９９６年５月～１９９７年２月住玉林地区红十字...     

Amplification of GB virus-C/hepatitis G virus RNA with primers from different regions of the viral genome

GB virus-C/hepatitis G virus (GBV-C/HGV) is a newly identified RNA virus. The aim of the study was to compare three primer pairs from the 5′ untranslated region (5′UTR), envelope region 2 (E 2) and nonstructural region 3 (NS 3) of GBV-C/HGV genome for their ability to detect GBV-C/HGV RNA by polymerase chain reaction (PCR) assays. By using PCR with primers from different regions of the viral genome, serum GBV-C/HGV RNA was assayed in 200 at-risk individuals. The sensitivity of this assay was assessed by a titration experiment, and nucleotide sequences of the amplified products were determined directly. Of 200 serum samples, 43 (21.5%) were positive for GBV-C/HGV RNA with at least one of the primer pairs. The positive rates by 5′UTR, NS 3, and E 2 primers were 100%, 98%, and 84%, respectively, and the sensitivity of PCR assays using 5′UTR primers was 10 to 100 times more likely to detect GBV-C/HGV RNA than that of NS 3 and E 2 primers. The average homology of amplified targets to the prototype HGV genome was 89%, 80%, and 85% and the similarity between each amplified target was up to 100%, 90%, and 92% in the 5′UTR, E 2, and NS 3 regions, respectively. Therefore, the 5′UTR of GBV-C/HGV genome is highly conserved and primers deduced from this region can provide a sensitive and specific PCR assay for GBV-C/HGV RNA. J. Med. Virol. 51:284–289, 1997. © 1997 Wiley-Liss, Inc.     

Profiles of GBV-C/hepatitis G virus markers in patients coinfected with hepatitis C virus.

GBV-C/Hepatitis G virus (GBV-C/HGV) is a newly discovered viral agent, found widely among healthy blood donors and among individuals at risk of parenterally transmitted infections. GBV-C/HGV is found frequently in coinfection with HCV. A population of 109 HCV positive patients was examined for the presence of GBV-C/HGV RNA and antibodies to E2. Of the 109 patients, 23 (21%) had serum GBV-C/HGV RNA in serum, 39 (36%) had only antibodies to E2 and 8 (7%) were positive for both markers, with an overall prevalence of 64%. Different serologic and virological patterns were observed in GBV-C/HGV exposed patients according to their infection status. Active infection was characterized by positive RT/PCR signal with primers for both the 5'UTR and NS5 genomic regions, viremia levels above 10(4) copies/mL by real time quantitative RT/PCR and absence of detectable anti-E2. In the transition phase between active infection and recovery, GBV-C/HGV RNA was only detectable by RT/PCR using primers from the 5' untranslated region and viremia levels were below 10(4) copies/ml by quantitative PCR, with or without simultaneous presence of anti-E2 antibodies. Resolved infection was characterized by absence of detectable viremia and, in most patients, by the presence of anti-E2.     

GBV-C/HGV infection in chronic hepatitis C patients: Its effect on clinical features and interferon therapy

A novel virus (GBV-C/HGV) may be associated with some liver diseases including fulminant hepatitis and acute and chronic hepatitis. On the other hand, many investigations showed that this infection does not contribute to liver disease. GBV-C/HGV has been found to occur in association with infection with other hepatitis viruses. We investigated the effect of GBV-C/HGV infection on the clinical features and interferon treatment in patients with chronic hepatitis C. A total of 262 hepatitis C virus (HCV) RNA positive patients with chronic hepatitis were examined in this study. The detection of serum GBV-C/HGV RNA was done by RT-PCR using specific primers from the NS5 regions. Interferon-alpha was given at a dose of 6 MU/day for 16 or 24 weeks. A responder was defined as a patient with ALT normalization and HCV RNA disappearance after treatment. GBV-C/HGV RNA was detected in 28 (11%) patients. No significant difference was detected in clinical features (age, sex, liver-related biochemical tests, and histological examination) between the 28 GBV-C/HGV-positive patients and the GBV-C/HGV-negative patients. Using interferon therapy for hepatitis C, the responder rates of GBV-C/HGV-positive and -negative patients were 14% and 20%, respectively. Of the 28 patients with GBV-C/HGV RNA, GBV-C/HGV RNA was tested after interferon therapy in 16 and of these GBV-C/HGV RNA was not detected in nine patients after therapy. These findings suggest that GBV-C/HGV infection dose not affect the clinical features in patients with HCV and the efficacy of interferon therapy for chronic hepatitis C. J. Med. Virol. 55:98–102, 1998. © 1998 Wiley-Liss, Inc.     

Detection of hepatitis G virus RNA in patients with hepatitis B,hepatitis C,and non-A-E hepatitis by RT-PCR using multiple primer sets

Hepatitis G virus(HGV)/GB virus C(GBV-C) is a newly identified virus associated with human hepatitis. The preliminary prevalence studies of HGV infection in Japan were entirely based on the detection of HGV RNA by RT-PCR. However, the selection of the different primer sets in such assay may influence sensitivity of the test because of the extensive genetic heterogeneity of HGV, and influence the estimation of the prevalence of HGV. To address this potential problem, we designed two primer sets from well conserved domains in the 5′NC and NS5 regions of HGV genome, and tested them together with the NS3-derived primer set in RT-PCR for their ability to detect HGV RNA in serial dilution of synthetic viral RNA templates. Subsequently, we used these three primer sets to detect HGV RNA in the sera of 371 Japanese patients with hepatitis B, hepatitis C, and non-A-E hepatitis. The results indicated that the primer set derived from the 5′NC region appeared to be most effective in detecting HGV RNA. The results also showed that only two out of the 126 patients (1.6%) with non-A-E hepatitis were positive for HGV RNA although the RNA were detected more frequently in patients with hepatitis B (2/38; 5.3%) and hepatitis C (17/207; 8.2%), suggesting that HGV is not a common causative agent for non-A-E hepatitis in Japan. J. Med. Virol. 52:385–390, 1997. © 1997 Wiley-Liss, Inc.